GLP-1 receptor agonist-based compounds are the most common drug class in late stage clinical trials
Airfinity launches world’s first obesity data and analytics platform
January 24, 2024 04:57 ET | Airfinity
London, England, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Today, Airfinity is launching the world’s first data and analytics platform dedicated to the breakthrough obesity treatments market.  ...